JP5941230B1 - 細胞傷害誘導治療剤 - Google Patents

細胞傷害誘導治療剤 Download PDF

Info

Publication number
JP5941230B1
JP5941230B1 JP2015549113A JP2015549113A JP5941230B1 JP 5941230 B1 JP5941230 B1 JP 5941230B1 JP 2015549113 A JP2015549113 A JP 2015549113A JP 2015549113 A JP2015549113 A JP 2015549113A JP 5941230 B1 JP5941230 B1 JP 5941230B1
Authority
JP
Japan
Prior art keywords
antibody
amino acid
variable region
seq
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015549113A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2016047722A1 (ja
Inventor
淳一 根津
淳一 根津
敦 成田
敦 成田
敬弘 石黒
敬弘 石黒
実香 櫻井
実香 櫻井
宙丈 白岩
宙丈 白岩
奈緒香 廣庭
奈緒香 廣庭
智之 井川
智之 井川
由美子 川合
由美子 川合
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP5941230B1 publication Critical patent/JP5941230B1/ja
Publication of JPWO2016047722A1 publication Critical patent/JPWO2016047722A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015549113A 2014-09-26 2015-09-25 細胞傷害誘導治療剤 Active JP5941230B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014197315 2014-09-26
JP2014197315 2014-09-26
PCT/JP2015/077024 WO2016047722A1 (ja) 2014-09-26 2015-09-25 細胞傷害誘導治療剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016023218A Division JP5941235B1 (ja) 2014-09-26 2016-02-10 細胞傷害誘導治療剤
JP2016100040A Division JP6718305B2 (ja) 2014-09-26 2016-05-19 細胞傷害誘導治療剤

Publications (2)

Publication Number Publication Date
JP5941230B1 true JP5941230B1 (ja) 2016-06-29
JPWO2016047722A1 JPWO2016047722A1 (ja) 2017-04-27

Family

ID=55581241

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015549113A Active JP5941230B1 (ja) 2014-09-26 2015-09-25 細胞傷害誘導治療剤
JP2016023218A Active JP5941235B1 (ja) 2014-09-26 2016-02-10 細胞傷害誘導治療剤
JP2016100040A Active JP6718305B2 (ja) 2014-09-26 2016-05-19 細胞傷害誘導治療剤
JP2020102042A Expired - Fee Related JP7054402B2 (ja) 2014-09-26 2020-06-12 細胞傷害誘導治療剤
JP2022061599A Ceased JP2022109914A (ja) 2014-09-26 2022-04-01 細胞傷害誘導治療剤
JP2024000380A Withdrawn JP2024029183A (ja) 2014-09-26 2024-01-05 細胞傷害誘導治療剤

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2016023218A Active JP5941235B1 (ja) 2014-09-26 2016-02-10 細胞傷害誘導治療剤
JP2016100040A Active JP6718305B2 (ja) 2014-09-26 2016-05-19 細胞傷害誘導治療剤
JP2020102042A Expired - Fee Related JP7054402B2 (ja) 2014-09-26 2020-06-12 細胞傷害誘導治療剤
JP2022061599A Ceased JP2022109914A (ja) 2014-09-26 2022-04-01 細胞傷害誘導治療剤
JP2024000380A Withdrawn JP2024029183A (ja) 2014-09-26 2024-01-05 細胞傷害誘導治療剤

Country Status (24)

Country Link
US (4) US9975966B2 (enExample)
EP (2) EP3199628A4 (enExample)
JP (6) JP5941230B1 (enExample)
KR (4) KR102548783B1 (enExample)
CN (2) CN107002068B (enExample)
AU (2) AU2015322543B2 (enExample)
BR (2) BR112017006061B1 (enExample)
CA (1) CA2960650C (enExample)
CL (3) CL2017000704A1 (enExample)
CO (1) CO2017004002A2 (enExample)
CR (2) CR20210331A (enExample)
EA (1) EA201790674A1 (enExample)
IL (2) IL250685B2 (enExample)
MA (1) MA40764A (enExample)
MX (2) MX2017003503A (enExample)
MY (1) MY187049A (enExample)
PE (1) PE20170704A1 (enExample)
PH (1) PH12017500507A1 (enExample)
RU (1) RU2743464C2 (enExample)
SA (1) SA517381167B1 (enExample)
SG (2) SG10201800851XA (enExample)
TW (7) TWI860574B (enExample)
UA (1) UA121661C2 (enExample)
WO (1) WO2016047722A1 (enExample)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
PL2647707T3 (pl) 2010-11-30 2019-02-28 Chugai Seiyaku Kabushiki Kaisha Środek terapeutyczny wywołujący cytotoksyczność
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
BR112015007120A2 (pt) 2012-10-08 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CN105143270B (zh) 2013-02-26 2019-11-12 罗切格利卡特公司 双特异性t细胞活化抗原结合分子
PT2961771T (pt) 2013-02-26 2020-02-28 Roche Glycart Ag Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP3053592B1 (en) 2013-10-01 2025-04-23 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
EP3736292B1 (en) 2013-12-17 2024-05-08 Genentech, Inc. Anti-cd3 antibodies and methods of use
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
WO2015174439A1 (ja) 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
FI3608337T3 (fi) 2014-08-04 2024-06-13 Hoffmann La Roche Bispesifisiä t-solua aktivoivia antigeenia sitovia molekyylejä
WO2016023019A2 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR20170066421A (ko) 2014-09-12 2017-06-14 제넨테크, 인크. 항-cll-1 항체 및 면역접합체
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN107074955B (zh) 2014-11-20 2021-06-22 豪夫迈·罗氏有限公司 针对FolR1和CD3的T细胞活化性双特异性抗原结合分子
MX387463B (es) 2014-11-20 2025-03-18 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas activadoras de células t y antagonistas de unión al eje de pd-1 y usos de los mismos para el tratamiento de cáncer.
RS60615B1 (sr) 2014-11-20 2020-08-31 Hoffmann La Roche Zajednički laki lanci i postupci upotrebe
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
PL3310814T3 (pl) 2015-06-16 2023-12-11 F. Hoffmann-La Roche Ag Humanizowane i wykazujące dojrzałe powinowactwo przeciwciała przeciwko FcRH5 i sposoby stosowania
WO2016205200A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cll-1 antibodies and methods of use
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MA43025A (fr) 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
RU2746754C2 (ru) 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
MY198233A (en) 2016-03-22 2023-08-15 Hoffmann La Roche Protease-Activated T Cell Bispecific Molecules
EP4050032A1 (en) 2016-06-28 2022-08-31 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3502250B1 (en) 2016-08-22 2024-04-24 Chugai Seiyaku Kabushiki Kaisha Gene-modified rodent expressing human gpc3 polypeptide
PL3519437T3 (pl) 2016-09-30 2022-01-17 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste przeciwko p95HER2
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2018203567A1 (en) * 2017-05-02 2018-11-08 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
RS64419B1 (sr) 2017-08-03 2023-09-29 Alector Llc Anti-trem2 antitela i postupci za njihovu upotrebu
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
EP3720963A4 (en) 2017-12-05 2021-12-08 Chugai Seiyaku Kabushiki Kaisha ANTIGEN-BINDING MOLECULE WITH CHANGED BINDING OF THE VARIABLE ANTIBODY REGIONS CD3 AND CD137
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
EP3860716A2 (en) 2018-10-01 2021-08-11 Adicet Bio Inc. Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
MX2021010039A (es) 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
BR112021019571A2 (pt) * 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
US20220324975A1 (en) 2019-06-05 2022-10-13 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site binding molecule
MA56131A (fr) * 2019-06-10 2022-04-13 Chugai Pharmaceutical Co Ltd Molécule de liaison à l'antigène anti-lymphocytes t à utiliser en association avec un inhibiteur de cytokines
WO2021006328A1 (en) 2019-07-10 2021-01-14 Chugai Seiyaku Kabushiki Kaisha Claudin-6 binding molecules and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
TWI895351B (zh) 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
WO2021200896A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Immune activating multispecific antigen-binding molecules and uses thereof
JP7644777B2 (ja) 2020-04-22 2025-03-12 ドラゴンフライ セラピューティクス， インコーポレイテッド ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
WO2021226321A2 (en) * 2020-05-07 2021-11-11 Phanes Therapeutics, Inc. Anti-tumor associated antigen antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
KR102594943B1 (ko) 2020-06-19 2023-10-27 추가이 세이야쿠 가부시키가이샤 혈관신생 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
US11780920B2 (en) 2020-06-19 2023-10-10 Hoffmann-La Roche Inc. Antibodies binding to CD3 and CD19
WO2022002112A1 (en) 2020-07-01 2022-01-06 Shandong Boan Biotechnology Co., Ltd. Anti-gpc3 antibody, anti-gpc3 chimeric antigen receptor and gpc3/cd3 bispecific antibody
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
US12516118B2 (en) 2020-11-04 2026-01-06 Genentech, Inc. Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies and anti-CD79b antibody drug conjugates
CA3196076A1 (en) 2020-11-04 2022-05-12 Chi-Chung Li Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
MX2023005132A (es) 2020-11-04 2023-05-25 Genentech Inc Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
CA3200860A1 (en) * 2020-11-16 2022-05-19 Astellas Pharma Inc. Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
CN114524878B (zh) * 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
AU2021399955A1 (en) 2020-12-18 2023-08-03 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
KR20240005691A (ko) 2021-04-30 2024-01-12 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
AU2022273541A1 (en) 2021-05-14 2023-11-30 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
CN119032110A (zh) * 2022-04-07 2024-11-26 恺兴生命科技(上海)有限公司 嵌合多肽及其应用
CN119654417A (zh) 2022-06-10 2025-03-18 富士胶片戴奥辛思生物技术英国有限公司 细胞的制备方法、异源多聚体蛋白质的制造方法、双特异性抗体的制造方法、载体组、哺乳动物细胞、cho细胞和细胞池的制备方法
CN116949156B (zh) * 2023-09-19 2023-12-08 美迪西普亚医药科技(上海)有限公司 一种基于核酸变体的通用型检测人t细胞的分析方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008118970A2 (en) * 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
JP2012082201A (ja) * 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
WO2013181543A1 (en) * 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014051433A1 (en) * 2012-09-27 2014-04-03 Merus B.V. BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体

Family Cites Families (339)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
SE370449B (enExample) 1970-08-29 1974-10-14 Philips Nv
JPS5334319B2 (enExample) 1971-12-28 1978-09-20
JPS5616428B2 (enExample) 1973-04-13 1981-04-16
JPS6048972B2 (ja) 1975-08-08 1985-10-30 株式会社日立製作所 方向比較搬送保護継電装置
JPS5816170B2 (ja) 1977-03-16 1983-03-30 旭化成株式会社 乾式画像形成材料
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5970B2 (ja) 1978-02-10 1984-01-05 エプソン株式会社 小型プリンタの紙送り機構
JPS55134615A (en) 1979-04-05 1980-10-20 Ishigaki Kiko Kk Removing device for cake in filter press
JPS5912436B2 (ja) 1980-08-05 1984-03-23 ファナック株式会社 工業用ロボットの安全機構
JPS6022444B2 (ja) 1980-11-08 1985-06-01 日立化成工業株式会社 集成マイカ材料，集成マイカプリプレグ材料及び集成マイカ製品
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6121424A (en) 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en) 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU649952B2 (en) 1989-12-11 1994-06-09 Immunomedics Inc. Method for antibody targeting of diagnostic or therapeutic agents
TW212184B (enExample) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
JPH04228089A (ja) 1990-05-15 1992-08-18 Kanegafuchi Chem Ind Co Ltd 高カルシウム血症治療・予防剤
JPH05184383A (ja) 1990-06-19 1993-07-27 Dainabotsuto Kk 二重特異性抗体
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
JPH05199894A (ja) 1990-08-20 1993-08-10 Takeda Chem Ind Ltd 二重特異性抗体および抗体含有薬剤
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JPH04336051A (ja) 1991-05-10 1992-11-24 Toshiba Corp 超音波診断装置
JPH05304992A (ja) 1991-06-20 1993-11-19 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JPH05203652A (ja) 1992-01-28 1993-08-10 Fuji Photo Film Co Ltd 抗体酵素免疫分析法
JPH05213775A (ja) 1992-02-05 1993-08-24 Otsuka Pharmaceut Co Ltd Ｂｆａ抗体
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
ZA936260B (en) 1992-09-09 1994-03-18 Smithkline Beecham Corp Novel antibodies for conferring passive immunity against infection by a pathogen in man
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0729976A1 (en) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
CA2177988A1 (en) 1993-12-03 1995-06-08 Kazuo Higuchi Expression vector for preparing an anti-body-variable-region library
JP3485266B2 (ja) 1994-05-20 2004-01-13 松下電器産業株式会社 プロセッサ
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
JP3053873B2 (ja) 1994-08-12 2000-06-19 イムノメディクス，インコーポレイテッド Ｂ細胞リンパ腫細胞および白血病細胞に特異的な免疫結合体およびヒト化抗体
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
EP2319535A3 (en) 1994-10-21 2011-08-31 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treatment of diseases caused by IL-6 production
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
DK0812136T3 (da) 1995-02-28 2001-02-19 Procter & Gamble Fremgangsmåde til fremstilling af ikke-kulsyreholdige læskedrikke med bedre mikrobiel stabilitet
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69633973T2 (de) 1995-09-11 2005-12-22 Kyowa Hakko Kogyo Co., Ltd. Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
AU720232B2 (en) 1996-07-19 2000-05-25 Amgen, Inc. Analogs of cationic proteins
KR100847441B1 (ko) 1996-09-26 2008-07-21 츄가이 세이야꾸 가부시키가이샤 인간의 부갑상선 호르몬 관련 펩티드에 대한 항체
UA76934C2 (en) 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3587664B2 (ja) 1996-10-04 2004-11-10 中外製薬株式会社 再構成ヒト抗ｈｍ１．２４抗体
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
JPH10165184A (ja) 1996-12-16 1998-06-23 Tosoh Corp 抗体、遺伝子及びキメラ抗体の製法
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
JP4228089B2 (ja) 1997-03-11 2009-02-25 株式会社ニコン 過電流検知機構およびそれを用いた電子閃光装置
JPH10256223A (ja) 1997-03-11 1998-09-25 Super Silicon Kenkyusho:Kk ウェーハ面取り部の枚葉処理装置
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7361336B1 (en) 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
BR9812846A (pt) 1997-10-03 2000-08-08 Chugai Pharmaceutical Co Ltd Anticorpo humanizado natural
JPH11118775A (ja) 1997-10-09 1999-04-30 Canon Inc 超音波検査装置
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US20030175884A1 (en) 2001-08-03 2003-09-18 Pablo Umana Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
JP3445153B2 (ja) 1998-06-04 2003-09-08 富士通株式会社 電話番号一時的使用装置及び方法
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
WO2000018806A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren
AU769125B2 (en) 1998-10-16 2004-01-15 Regents Of The University Of California, The Glypicans for the detection and treatment of human carcinoma
CN1214043C (zh) 1998-12-01 2005-08-10 蛋白质设计实验室股份有限公司 抗γ－干扰素的人化抗体
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
DK1156823T3 (da) 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
TWI290832B (en) 1999-08-23 2007-12-11 Chugai Pharmaceutical Co Ltd Expression enhancer for HM1.24 antigen
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
JP3606132B2 (ja) 1999-10-14 2005-01-05 Ｊｆｅエンジニアリング株式会社 超音波探傷方法およびその装置
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
EP1278512A2 (en) 2000-05-03 2003-01-29 MBT Munich Biotechnology AG Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
JP2002048867A (ja) 2000-08-07 2002-02-15 Mitsubishi Heavy Ind Ltd 音響探査装置
WO2002022739A1 (en) 2000-09-12 2002-03-21 Union Carbide Chemicals & Plastics Polymer composites containing alkylene oxide copolymers
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
AU2002226930A1 (en) 2000-11-17 2002-05-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point
US7361343B2 (en) 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
EP1250023A1 (en) 2001-04-11 2002-10-16 Alcatel Provision of subscriber QoS guarantees to roaming subscribers
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Ｖｌａ-1에 대한 항체들
JP3642316B2 (ja) 2001-06-15 2005-04-27 日本電気株式会社 化学増幅レジスト用単量体、化学増幅レジスト用重合体、化学増幅レジスト組成物、パターン形成方法
DE60237929D1 (de) 2001-06-22 2010-11-18 Chugai Pharmaceutical Co Ltd Zellproliferationshemmer, die Anti-Glypican 3 Antikörper enthalten
DE10136273A1 (de) 2001-07-25 2003-02-13 Sabine Debuschewitz Molekulare Marker beim hepatozellulären Karzinom
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
WO2003028696A2 (en) 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
BR0213761A (pt) 2001-10-25 2005-04-12 Genentech Inc Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição
DE10156482A1 (de) 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
KR100572236B1 (ko) 2001-11-14 2006-04-19 가부시끼가이샤 도시바 초음파 검사 장치, 초음파 트랜스듀서 및 초음파 화상화 장치
JP4087098B2 (ja) 2001-11-14 2008-05-14 株式会社東芝 超音波検査装置
JP3961359B2 (ja) 2002-07-18 2007-08-22 株式会社東芝 超音波画像化装置
JP2003157075A (ja) 2001-11-22 2003-05-30 Kawai Musical Instr Mfg Co Ltd 電子楽器のパラメータ入力装置
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US20030224397A1 (en) 2002-02-11 2003-12-04 Genentech, Inc. Antibody variants with faster antigen association rates
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US8030461B2 (en) 2002-04-15 2011-10-04 Chugai Seiyaku Kabushiki Kaisha Methods for constructing scDb libraries
WO2003091424A1 (fr) 2002-04-26 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Procede de criblage d'un anticorps agoniste
EP1506406B1 (en) 2002-05-23 2009-03-11 Sunnybrook and Women's College Health Sciences Centre Diagnosis of hepatocellular carcinoma
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
WO2003107218A1 (ja) 2002-05-31 2003-12-24 セレスター・レキシコ・サイエンシズ株式会社 相互作用予測装置
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7750204B2 (en) 2002-06-05 2010-07-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing antibody
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
EP1539947A4 (en) 2002-08-15 2006-09-06 Epitomics Inc HUMANIZED RABBIT ANTIBODIES
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
AU2002328429A1 (en) 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004023145A1 (ja) 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
ATE540978T1 (de) 2002-10-17 2012-01-15 Genmab As Humane monoklonale antikörper gegen cd20
DE602004021095D1 (de) * 2003-01-21 2009-06-25 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
CA2521414A1 (en) 2003-04-02 2004-10-21 Celator Pharmaceuticals, Inc. Methods to individualize combination therapy
GB2400851B (en) 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
RU2337107C2 (ru) 2003-05-02 2008-10-27 Ксенкор, Инк. ОПТИМИЗИРОВАННЫЕ Fc-ВАРИАНТЫ, ИМЕЮЩИЕ ИЗМЕНЕННОЕ СВЯЗЫВАНИЕ С FcγR, И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
US6921978B2 (en) 2003-05-08 2005-07-26 International Business Machines Corporation Method to generate porous organic dielectric
EP1629010A1 (en) 2003-05-30 2006-03-01 Genentech, Inc. Treatment with anti-vegf antibodies
CA2528434A1 (en) 2003-06-05 2005-01-06 Genentech, Inc. Combination therapy for b cell disorders
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
JP2005053541A (ja) 2003-08-05 2005-03-03 Toppan Printing Co Ltd 紙容器用積層材料及びそれを用いた紙容器
WO2005023301A1 (ja) 2003-09-04 2005-03-17 Chugai Seiyaku Kabushiki Kaisha 胆管癌治療剤および検出薬
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
IN2009KN02655A (enExample) 2003-12-10 2015-10-23 Medarex Inc
WO2005062916A2 (en) 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
US20050266425A1 (en) 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
DE602005026779D1 (de) 2004-01-09 2011-04-21 Pfizer ANTIKÖRPER GEGEN MAdCAM
ITBO20040008U1 (it) 2004-02-03 2004-05-03 Tonazzi S R L Macchina per il riempimento e la chiusura di tubetti
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
JP4223981B2 (ja) 2004-03-24 2009-02-12 学校法人東海大学 ホルムアルデヒド検知材料およびその製造方法
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
JP4658926B2 (ja) 2004-04-28 2011-03-23 株式会社ペルセウスプロテオミクス 肝癌治療後の再発予測判定薬
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
CA2569277A1 (en) 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
DE102004032634A1 (de) 2004-07-06 2006-02-16 Sms Demag Ag Verfahren und Einrichtung zum Messen und Regeln der Planheit und/oder der Bandspannungen eines Edelstahlbandes oder einer Edelstahlfolie beim Kaltwalzen in einem Vielwalzengerüst, insbesondere in einem 20-Walzen-Sendizimir-Walzwerk
DE602005024502D1 (de) 2004-07-09 2010-12-16 Chugai Pharmaceutical Co Ltd Anti-glypican-3-antikörper
JP4331227B2 (ja) 2004-07-09 2009-09-16 中外製薬株式会社 抗グリピカン３抗体
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
ES2426816T3 (es) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Regiones Fc variantes
US20060040325A1 (en) 2004-08-16 2006-02-23 Medimmune, Inc. Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity
WO2006022407A1 (ja) 2004-08-24 2006-03-02 Chugai Seiyaku Kabushiki Kaisha 抗グリピカン３抗体を用いたアジュバント療法
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
WO2006031825A2 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2585196C (en) 2004-10-26 2015-01-06 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
AR051800A1 (es) 2004-12-15 2007-02-07 Wyeth Corp Anticuerpos a beta usados en mejorar la cognicion
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
NZ556788A (en) 2005-01-05 2011-03-31 Biogen Idec Inc Humanized CRIPTO binding molecules with CDRs from murine B3F6
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CN101171263A (zh) 2005-03-04 2008-04-30 比奥根艾迪克Ma公司 通过合理修饰互补决定区残基使免疫球蛋白可变区人源化的方法
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
JP5047947B2 (ja) 2005-05-05 2012-10-10 デューク ユニバーシティ 自己免疫疾患のための抗ｃｄ１９抗体治療
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
JP5068167B2 (ja) 2005-06-10 2012-11-07 中外製薬株式会社 メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
EP1925319B1 (en) 2005-06-10 2018-03-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
JP5072595B2 (ja) 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
HUE025240T2 (en) 2005-08-19 2016-03-29 Wyeth Llc Anti-GDF-8 antagonist antibodies and their use in the treatment of ALS and other disorders associated with GDF-8
WO2007030571A2 (en) 2005-09-06 2007-03-15 Molecular Image Inc. Identification of targets and development of reagents for testing and molecular imaging of human disease
JP2007093274A (ja) 2005-09-27 2007-04-12 Perseus Proteomics Inc 癌の診断方法および治療薬
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007053573A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
US20070185069A1 (en) 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7723043B2 (en) 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
BRPI0707671A2 (pt) 2006-02-09 2011-05-10 Daiichi Sankyo Co Ltd composiÇço farmacÊutica anti-cÂncer
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007099988A1 (ja) 2006-02-28 2007-09-07 Kyowa Hakko Kogyo Co., Ltd. α-1,6-フコシルトランスフェラーゼ変異体とその用途
JP2007256063A (ja) 2006-03-23 2007-10-04 Seiko Epson Corp 表示装置、および、電子機器
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
WO2007145941A2 (en) 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
EP2047863B1 (en) 2006-06-08 2013-07-31 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
GB2440721A (en) 2006-08-11 2008-02-13 Univ Cambridge Tech Composite biomaterial formed by cooling a fluid composition on a porous solid and removing solidified crystals of the liquid carrier
JP4463793B2 (ja) 2006-10-10 2010-05-19 浜松ホトニクス株式会社 光検出装置
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
EP2107115A1 (en) 2007-01-24 2009-10-07 Kyowa Hakko Kirin Co., Ltd. Genetically recombinant antibody composition capable of binding specifically to ganglioside gm2
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
WO2009011941A2 (en) 2007-04-04 2009-01-22 The Government Of U.S.A., As Represented By The Secretary, Departmetnt Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
AU2008270710A1 (en) 2007-06-29 2009-01-08 Merck Sharp & Dohme Corp. MDL-1 uses
PL2178921T3 (pl) 2007-07-17 2016-06-30 Squibb & Sons Llc Monoklonalne przeciwciała przeciwko glipikanowi-3
MY162534A (en) 2007-09-26 2017-06-15 Chugai Pharmaceutical Co Ltd Anti-il-6 receptor antibody
BRPI0817294A2 (pt) 2007-09-26 2015-03-17 Chugai Pharmaceutical Co Ltd Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
TWI563002B (en) 2007-09-26 2016-12-21 Chugai Pharmaceutical Co Ltd Antibody constant region mutant
RU2445366C2 (ru) 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
JP5314033B2 (ja) 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
BRPI0909672B1 (pt) 2008-03-17 2018-09-18 Chugai Seiyaku Kabushiki Kaisha método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo
WO2009120922A2 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfrbeta and vegf-a
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN101377506A (zh) 2008-04-16 2009-03-04 北京科美东雅生物技术有限公司 磷脂酰肌醇蛋白聚糖-3化学发光免疫分析测定试剂盒及其制备方法
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
DE102008042377A1 (de) 2008-09-25 2010-04-01 Robert Bosch Gmbh Audioverstärker mit Lastanpassung sowie Verfahren zur Lastanpassung des Audioverstärkers
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010034441A1 (en) 2008-09-26 2010-04-01 F. Hoffmann-La Roche Ag Bispecific anti-egfr/anti-igf-1r antibodies
KR101901458B1 (ko) * 2008-10-10 2018-09-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｔｃｒ 복합체 면역치료제
DE202008016028U1 (de) 2008-12-04 2010-04-15 Melitta Haushaltsprodukte Gmbh & Co. Kg Behälter zur Aufbewahrung von Gegenständen
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
SG10201402960SA (en) 2009-03-05 2014-08-28 Abbvie Inc IL-17 Binding Proteins
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY152963A (en) 2009-06-26 2014-12-15 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
JP2011118775A (ja) 2009-12-04 2011-06-16 Sony Corp 検索装置、検索方法、及び、プログラム
JP6087054B2 (ja) 2009-12-25 2017-03-01 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
KR101913440B1 (ko) 2010-03-02 2018-10-30 교와 핫꼬 기린 가부시키가이샤 개변 항체 조성물
PE20130393A1 (es) 2010-03-11 2013-04-07 Rinat Neuroscience Corp Anticuerpos con union de antigenos dependiente de ph
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
EP4477668A3 (en) 2010-04-20 2025-03-19 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
DK2606064T3 (en) 2010-08-16 2015-04-20 Novimmune Sa Methods for generating multispecific and multivalent antibodies
US9562109B2 (en) 2010-11-05 2017-02-07 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
EP2662385A4 (en) 2011-01-07 2015-11-11 Chugai Pharmaceutical Co Ltd METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
RU2608504C2 (ru) 2011-02-25 2017-01-18 Чугаи Сейяку Кабусики Кайся FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
EP2699603B1 (en) 2011-04-19 2016-03-02 The United States of America As Represented by the Secretary Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2013060867A2 (en) 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
US11851476B2 (en) 2011-10-31 2023-12-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
WO2014067011A1 (en) 2012-11-02 2014-05-08 Zymeworks Inc. Crystal structures of heterodimeric fc domains
SG10201704849PA (en) 2012-02-09 2017-07-28 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CA2860369A1 (en) 2012-03-02 2013-09-06 Roche Glycart Ag Predicitive biomarker for cancer treatment with adcc enhanced antibodies
MX366813B (es) * 2012-04-20 2019-07-25 Aptevo Res & Development Llc Polipeptidos de enlace cd3.
KR20200126007A (ko) 2012-04-20 2020-11-05 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
JP2015531751A (ja) 2012-07-23 2015-11-05 ザイムワークス，インコーポレイテッド 選択的対である軽鎖および重鎖を含む免疫グロブリン構築物
EP2882778B1 (en) 2012-08-13 2018-04-11 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
EP2905290B1 (en) 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
KR102282691B1 (ko) 2013-09-30 2021-07-27 추가이 세이야쿠 가부시키가이샤 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법
US11485790B2 (en) 2014-04-07 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
TWI735410B (zh) 2014-05-08 2021-08-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投予的ｇｐｃ３標的治療劑
WO2015174439A1 (ja) 2014-05-13 2015-11-19 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3233921B1 (en) 2014-12-19 2021-09-29 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6175590B1 (ja) 2016-03-14 2017-08-02 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
RU2746754C2 (ru) * 2016-03-14 2021-04-20 Чугаи Сейяку Кабусики Кайся Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012082201A (ja) * 2005-04-08 2012-04-26 Chugai Pharmaceut Co Ltd 血液凝固第ｖｉｉｉ因子の機能代替抗体
WO2008118970A2 (en) * 2007-03-27 2008-10-02 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
WO2012073985A1 (ja) * 2010-11-30 2012-06-07 中外製薬株式会社 細胞傷害誘導治療剤
WO2013181543A1 (en) * 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
WO2014051433A1 (en) * 2012-09-27 2014-04-03 Merus B.V. BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERCHANT, A.M. ET AL.: ""An efficient route to human bispecific IgG."", NATURE BIOTECHNOLOGY, vol. 16, no. 7, JPN6015050383, July 1998 (1998-07-01), pages 677 - 681, XP002141015, ISSN: 0003302192, DOI: 10.1038/nbt0798-677 *

Also Published As

Publication number Publication date
UA121661C2 (uk) 2020-07-10
EP3199628A4 (en) 2018-06-06
SG10201800851XA (en) 2018-03-28
JP6718305B2 (ja) 2020-07-08
AU2015322543A1 (en) 2017-03-30
CR20170124A (es) 2017-05-31
RU2017113731A3 (enExample) 2019-09-20
KR20210121268A (ko) 2021-10-07
CA2960650A1 (en) 2016-03-31
TWI716979B (zh) 2021-01-21
CL2017000704A1 (es) 2017-12-01
TW202448941A (zh) 2024-12-16
IL250685B1 (en) 2023-07-01
SA517381167B1 (ar) 2022-03-07
KR101777077B1 (ko) 2017-09-08
IL296444A (en) 2022-11-01
KR102305980B1 (ko) 2021-09-27
TW202100558A (zh) 2021-01-01
AU2021202614B2 (en) 2024-07-25
MX2022014342A (es) 2022-12-13
RU2743464C2 (ru) 2021-02-18
TW202332697A (zh) 2023-08-16
US9975966B2 (en) 2018-05-22
BR122020025720B1 (pt) 2024-04-30
JP2016196468A (ja) 2016-11-24
TWI724889B (zh) 2021-04-11
AU2015322543B2 (en) 2021-04-01
EP3199628A1 (en) 2017-08-02
TW202134283A (zh) 2021-09-16
BR112017006061B1 (pt) 2024-04-30
US20170267783A1 (en) 2017-09-21
CL2020001513A1 (es) 2020-11-06
MY187049A (en) 2021-08-27
CO2017004002A2 (es) 2017-09-20
EA201790674A1 (ru) 2017-08-31
CL2022000934A1 (es) 2023-01-20
MA40764A (fr) 2017-08-01
BR112017006061A2 (pt) 2017-12-19
US20180244805A1 (en) 2018-08-30
JP2022109914A (ja) 2022-07-28
JP2024029183A (ja) 2024-03-05
EP4640236A2 (en) 2025-10-29
KR20230101934A (ko) 2023-07-06
KR20160135840A (ko) 2016-11-28
TW201942137A (zh) 2019-11-01
TWI860574B (zh) 2024-11-01
KR102548783B1 (ko) 2023-06-27
TWI860447B (zh) 2024-11-01
US20210230311A1 (en) 2021-07-29
CA2960650C (en) 2023-08-29
CN107002068B (zh) 2021-07-09
TWI597290B (zh) 2017-09-01
US11001643B2 (en) 2021-05-11
CN113388038A (zh) 2021-09-14
NZ730615A (en) 2021-10-29
SG11201701119RA (en) 2017-03-30
TW201619193A (zh) 2016-06-01
PH12017500507A1 (en) 2017-08-30
IL250685B2 (en) 2023-11-01
PE20170704A1 (es) 2017-06-14
JP2020141709A (ja) 2020-09-10
TW201730209A (zh) 2017-09-01
MX2017003503A (es) 2017-05-30
CN107002068A (zh) 2017-08-01
TWI717507B (zh) 2021-02-01
RU2017113731A (ru) 2018-10-22
AU2021202614A1 (en) 2021-05-27
JPWO2016047722A1 (ja) 2017-04-27
US20250250362A1 (en) 2025-08-07
JP7054402B2 (ja) 2022-04-13
JP2016166174A (ja) 2016-09-15
JP5941235B1 (ja) 2016-06-29
CR20210331A (es) 2021-07-20
KR20170104635A (ko) 2017-09-15
IL250685A0 (en) 2017-04-30
WO2016047722A1 (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
JP7054402B2 (ja) 細胞傷害誘導治療剤
RU2812875C1 (ru) Индуцирующий цитотоксичность терапевтический агент
HK40056927A (en) Cytotoxicity-inducing therapeutic agent
NZ730615B2 (en) Cytotoxicity-inducing therapeutic agent
HK1234781B (zh) 诱导细胞毒性的治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151027

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20151027

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20151201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160519

R150 Certificate of patent or registration of utility model

Ref document number: 5941230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250